

## Product datasheet for TL305755

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

#### **C8orf4 Human shRNA Plasmid Kit (Locus ID 56892)**

#### **Product data:**

**Product Type:** shRNA Plasmids

**Product Name:** C8orf4 Human shRNA Plasmid Kit (Locus ID 56892)

Locus ID:

C8orf4; TC-1; TC1 Synonyms:

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Puromycin Selection:

Format: Lentiviral plasmids

Components: C8orf4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 56892).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

NM 020130, NM 020130.1, NM 020130.2, NM 020130.3, NM 020130.4, BC021672, RefSeq:

BC021672.1, BC020623, BM976768

UniProt ID: **09NR00** 

This gene encodes a small, monomeric, predominantly unstructured protein that functions **Summary:** 

as a positive regulator of the Wnt/beta-catenin signaling pathway. This protein interacts with

a repressor of beta-catenin mediated transcription at nuclear speckles. It is thought to

competitively block interactions of the repressor with beta-catenin, resulting in up-regulation of beta-catenin target genes. The encoded protein may also play a role in the NF-kappaB and ERK1/2 signaling pathways. Expression of this gene may play a role in the proliferation of

several types of cancer including thyroid cancer, breast cancer and hematological


malignancies. [provided by RefSeq, Nov 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact techsupport@origene.com.

If you need a special design or shRNA sequence, please utilize our custom shRNA service.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).